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Angiosarcoma is a rare vascular malignant soft tissue tumor, with highly malignant, invasive, and multifocal characteristics of
biology, which is prone to local recurrence and distant metastasis, so the prognosis is extremely poor. It rarely involves the
diaphragm. We present the case of an adult patient who had a primary giant angiosarcoma of the left-sided diaphragm.
1.Introduction
Angiosarcoma is a rare vascular malignant tumor originat-
ing from the endothelial cells in small blood vessels, which
represents 1-2% of soft tissue tumors [1, 2]. It may interest
a variety of organs but usually occurs in the skin, breast, soft
tissue, spleen, heart, liver, and skeletal muscles [3]. Clinical
report is rare for giant diaphragmatic angiosarcoma of adult
truly, so the experiences of its diagnosis and treatment are
particularly valuable. We report a case of primary giant
angiosarcoma of the left-sided diaphragm and compare our
experience with a literature review.
2.CaseReport
A 58-year-old woman had a left-sided chest distress and
short breath for more than one month duration. No other
symptoms such as fever, ague, cough, emptysis, hemoptysis,
nightsweat,andfatigueweredetected.High-densityshadow
was found in lower left chest after chest ﬁlm examination,
andthefurtherCTrevealedamassopacitieswithinhomoge-
neous density and slight enhancement in lower left thoracic
cavity, and no mediastinal lymph nodes, as well as a small
amount of eﬀusion (see Figure 1). We found a large number
of lymphocytes and mesothelial cells by analysing pleural
eﬀusion, but no cancer cells or acid-fast bacilli. Meanwhile,
CAl25 was signiﬁcantly increased and reached 452.4U/mL
in tumor marker detection. Comprehensive consideration
suggests that the mass opacities in left thoracic cavity may
be a tumor. After performing an exploratory thoracotomy
under general anaesthesia, the 20cm × 15cm × 18cm
lobulatedsubstantialmass,whosebasalpartwas6cm ×5cm
and closely linked with segmentum lingulare as well as lower
lobe, was conﬁrmed located in left diaphragm. The frozen
section of left diaphragm mass was diagnosed as malignant
tumor, which is also known as angiosarcoma. Then, tumor
was removed entirely.
3.Histology andImmunohistology
Upright ﬂuorescence microscope was used for watch. Biopsy
of the lesion showed irregular channels and ecstatic vascular
spaces lined by plump hyperchromatic endothelial cells. The
histology results were most compatible with moderately
diﬀerentiated angiosarcoma, as shown in Figure 2,i nl o w
magniﬁcation (L) and high magniﬁcation (R). The diagnosis
result was supported by the immunophenotypes CD34
(++) (see Figure 3), CD31 (+), Vimentin (+), epithelial
membrane antigen [EMA(−)] phosphoenolpyruvate car-
boxykinase [PCK(−)], factor VIII related antigen [FVIII
(−)], as well.2 Case Reports in Medicine
Figure 1: CT ﬁndings of angiosarcoma of the diaphragm (tumors
were located under the chest, a huge volume, heterogeneous en-
hancement, No mediastinal lymph nodes).
4. PostoperativeRadiotherapy andFollowup
After surgical treatment, the patient recovery was smoothly.
Due to the multifocal and invasive characteristic of angiosar-
coma, and combined with limited resection of the left-sided
diaphragm, radiotherapy postoperatively 3 weeks later was
used. The patient was treated by 3-dimensional conformal
radiotherapy (3DCRT), the clinical target including the left
side of diaphragm and the part of the lung tissues which
adhered to the angiosarcoma. A dose of 60Gy in 2Gy
fractions was given to 90% isodose volume in 3DCRT. In
view of the eﬀect is not clear, postoperative chemotherapy
was not used. She was good by following up in outpa-
tient department, and CAl25 was signiﬁcantly decreased to
63.0U/mL one month after radiotherapy.
5. Discussions
Angiosarcoma with low morbidity and high invasiveness
is evolved from endothelial cells or their derivatives of
mesenchymal cells. Its incidence may be related to these
factors, such as long-term chronic lymphedema, ionizing
radiation, chemical exposure, trauma, and chronic infection
[4], but the speciﬁc mechanic is unclear. Angiosarcoma
could occur in any part of the body [3], but the primary
angiosarcoma in the diaphragm is rare and there are few
clinical reports.
Clinical manifestations of angiosarcoma are diverse, and
its clinical features and imaging ﬁndings are diﬀerent from
diﬀerentparts[2,5].Thepatientsshowedsymptomsofchest
tightness, shortness of breath for over one month, and CT
revealed a huge heterogeneous mass in lower left thoracic
cavity. The time of clinical symptoms was not long, but the
volume of tumor was huge, and indicated angiosarcoma of
diaphragm has the characteristics of occult and fast growing.
This may be related to tumor location of the anatomical
characteristics, such as the huge volume of the chest, the
elastomeric characteristics of lungs and heart; these factors
might be conducive to tumor growth and be diﬃcult to be
found in the early days.
(a) (×40)
(b) (×200)
Figure 2: Histopathological microscopic structure of diaphragm
angiosarcoma (tumor cell atypia, abnormal vessel-like cavities
structure).
Figure 3: Epithelioid cells strongly positive with CD34 (×200).
The diagnosis of angiosarcoma mainly depends on the
histomorphological checks, and the immunohistochemistry
has great signiﬁcance for the diagnosis and diﬀerential diag-
nosis of angiosarcoma [5–7]. Vimentin, CD31, CD34, and
FVIII factors are the speciﬁc makers of tumors from blood
vessels. Studies show that when vimentin demonstrates
positive, a vascular tumor should be suspected. Further
more, when CD31, CD34, and FVIII and other endothelial
cells speciﬁc makers demonstrate positive, then this supportsCase Reports in Medicine 3
diagnosis of the angiosarcoma [1, 8, 9]. In this case, the
tumor maker of CA125 increased, and, in the course of the
operation, it was found that the tumor stemmed from the
left diaphragms. In addition to the histological diagnosis
and immunohistochemical examinations, we could deﬁne
the diagnosis of the diaphragmatic angiosarcoma. It is
worth noting that the clinical diagnosis of diaphragmatic
angiosarcoma requires identiﬁcation with lung cancer. The
author believes that CT features can be used as identiﬁcation
of key points, and angiosarcoma of diaphragm showed
the tumor located in the lower left thoracic cavity, rare
mediastinal and hilar lymph node metastasis. And lung
cancer often has mediastinal or hilar lymph node metastases.
Secondly, the clinical manifestations of angiosarcoma of
diaphragm are diﬀerent from lung cancer (such as cough,
hemoptysis, expectoration, and chest pain).
There is still no standard therapeutic method of
angiosarcoma to follow. Surgical treatment, radiotherapy,
chemotherapy, immune therapy, and other comprehensive
therapy treatment are often adopted. Surgical excision is
the main treatments of angiosarcoma. Radiotherapy or
chemotherapy before or after the operation may reduce the
local recurrence and metastasis [5, 10, 11]. Owing to the
multifocal and invasive characteristic of the angiosarcoma,
postoperative adjuvant radiotherapy can help increase the
localc ontr olrat es[5,12].Intermsoftimedosefractionation
(TDF), it is suggested that the multifocal and ill-deﬁned
angiosarcoma be given the doses of 60∼70Gy in order to
achieve a better curative eﬀect [13]. In this case, after the
completeresectionofthetumors,a3-dimensionalconformal
radiotherapy is adopted. A dose of 60Gy in 2Gy fractions
wasgivento90%isodosevolume,andthepatientsreactwell,
with light nausea.
The prognosis of angiosarcoma is bad [2, 5]. The factors
which markedly eﬀect its prognosis include (1) the initial
condition of the patients, namely, that the curative eﬀect of
primary cases is signiﬁcantly better than that of the recurrent
ormetastaticcases[14];(2)operationmethodandoperation
quality [14, 15], the curative eﬀect of the patients who have
the radical operation is better; (3) the tumor size may also
inﬂuence the prognosis. Studies show that when the tumor
diameter is larger than 10cm, the prognosis is poorer than
that when less than 10cm [16]. The tumor of this case is
huge,largerthan10cm.However,becauseofitsshortfollow-
up time, its survival time and quality of life are still under the
follow-up observation.
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